Co-director of WHRI
Mark Caulfield graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and translational clinical research. In 2007, 2009 and 2011 his research has been independently rated amongst the top ten scientific discoveries in his field. In 2009 he won the Lily Prize of the British Pharmacology Society. Since 2008 he directs the Barts National Institute of Health Research Cardiovascular Biomedical Research Unit. He was appointed Director of William Harvey Research Institute in 2002 and was elected to the Academy of Medical Sciences in 2008 and was President of the British Hypertension Society (2009-2011). He is an NHS consultant in the Barts Blood Pressure Clinic within the Barts/William Harvey European Society of Hypertension Centre of Excellence. He raised £25m toward the William Harvey Heart Centre which created a translational clinical research centre and was the academic leader that created the Barts Heart Centre bringing 3 hospitals together at Barts in 2015 to create the UK’s largest heart centre (includes UCLH Heart Hospital, the London Chest Hospital and Barts) http://www.bartshealth.nhs.uk/bartsheartcentre . He served on the 2011 NICE Guideline Group for hypertension and leads the Joint UK Societies’ Working Group and Consensus on Renal Denervation. In 2014 he became one of the top 200 most highly cited researchers in the world in genomics according to Thomson Reuters http://highlycited.com/ .
In 2013 he was appointed Chief Scientist for Genomics England, charged with delivery of the 100,000 Genomes Project on whole genome sequencing in rare disease, cancer and infection www.genomicsengland.co.uk. As chief scientist Mark leads on all scientific activities for Genomics England. He engages with NHS scientific teams and the general public to promote, explain and enthuse about the 100,000 Genomes Project. Mark also oversees the Clinical Interpretation Partnership.
Summary of Research
Since 1996 he has been National Co-ordinator of the MRC British Genetics of Hypertension (BRIGHT) Study on behalf of 5 UK Universities www.brightstudy.ac.uk. He led the hypertension study within the Wellcome Trust Case Control Consortium and has since formed and co-leads the Global BP gen consortium and International Consortium for Blood Pressure Genomewide Studies which combined the talents of 354 scientists from 224 Institutions from 24 Countries. This work has now identified over 80 genes for high blood pressure and 5 genes influencing statin response.
Cardiovascular Clinical Trials:
He was on the Steering Group of the Anglo-Scandinavian Cardiac Outcome Trial recruiting 1157 hypertensives www.whri.qmul.ac.uk/whricrc. This trial has changed international guidance on lipid lowering and blood pressure treatment. From this Barts and The London now have a major clinical trials programme and a partnership with Quintiles Transnational to enhance clinical research.
Members of the Group
Office of the William Harvey/NIHR Biomedical Research Unit Co-Director’s: Sabrina Kelly Williams (Executive Assistant), Nina Ravic (Education Manager) Denise Elliot (Institute Manager) Steve Coppen (Deputy Institute Manager), Mark Johnson (Joint Strategic Director for Barts Heart Centre/WHRI and the NIHR Biomedical Research Unit)
Cardiovascular Genomics: Vacancy (Laboratory manager); Dr Fu Ng (clinical Fellow); Dr Kate Witowska (Postdoctoral Scientist); Dr Helen Warren (Statistical Geneticist); Dr Claudia Cabrera (Bioinformatician); Dr Mike Barnes (Director of Bioinformatics); Rosie Zhang (PhD Student); Meixia Ren (PhD student).
William Harvey Clinical Research Centre: Dr Vivienne Monk (Clinical Research Centre Manager); Dr David Collier (Co- Director); Dr Manish Saxena (Clinical Fellow); Dr Julian Shiel (Clinical Fellow), Anne Zak (Senior Nurse Manager); Mary Feely (Feasibility and startup); Marion Benford (Quality Assurance); Mike Taylor (recruitment) Patrizia Ebano, Jo Hadley, Nirmala Markandu (Research Sisters).
For a full list of publist publications click here
* denotes joint last author and # denotes corresponding author.
Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, then 60 co-authors then Colhoun HM, Hitman G, Krauss RM, Wouter Jukema J*, Caulfield MJ*. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014 Oct 28;5:5068. doi: 10.1038/ncomms6068.
Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases:
lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014 May 31;383(9932):1899-911. doi: 10.1016/S0140-6736(14)60685-1.
Kottgen A*, then co-authors then Caulfield M*, Bochud M*, Geiger C*. Multiple Novel Loci Highlighting Metabolic Control of Urate Production and Excretion are Associated with Gout. Nature Genetics 2013. Feb;45(2):145-54. doi: 10.1038/ng.2500. Epub 2012 Dec 23.
Georg B. Ehret*, then 346 co-authors then Bruce M. Psaty*, Gonçalo R Abecasis*, Aravinda Chakravarti*, Paul Elliott*, Cornelia M. van Duijn*, Christopher Newton-Cheh*#, Daniel Levy*##, Mark J. Caulfield*##, Toby Johnson*. Genetic variants from novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011;478 (7367):103-9. Voted top 5 paper in CV research and number 1 in stroke by the American Heart Association.
Louise V Wain*, then 248 co-authors- then Mark J Caulfield*, Dabeeru C Rao*, Martin D Tobin*#, Paul Elliott*#, Cornelia M van Duijn*#. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nature Genetics 2011; 43(10):1005-11.
Wellcome Trust Case Control Consortium. Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls (Caulfield is a co-PI). Nature. 2010; 464 (7289):713-20.
Christopher Newton-Cheh*#, then 165 co-authors then Mark Caulfield*#, Patricia B Munroe*#. Eight blood pressure loci identified by genome-wide association study of 34,433 people. Nature Genetics 2009; 41:666-676. Voted American Heart Association Top ten paper in worldwide CV research in 2009.
Caulfield MJ, et al. (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5(9): e197.
Wellcome Trust Case Control Consortium (Caulfield co-PI). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661-678. Voted Best Scientific Research Paper in the World in 2007 (by both Nature and Science).
Barter PJ, Caulfield M, etal. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine. 2007 Nov 22;357(21):2109-22.
Internal: Prof Patricia Munroe; Prof Shu Ye; Prof Amrita Ahluwalia; Prof Adrian Hobbs; Dr Steffen Petersen; Prof Chris Thiemermann; Prof Adam Timmis; Prof Cos Pitzalis; Dr Mel Lobo
Professor Mark Caulfield, FMedSci
Director of the William Harvey Research Institute and Barts Cardiovascular Biomedical Research Unit
Centre for Clinical Pharmacology
William Harvey Research Institute
Barts and The London, Queen Mary's School of Medicine and Dentistry
John Vane Science Centre
London, EC1M 6BQ
T: +44 (0) 20 7882 3403